NCT03510767: A Study of TQ-B3525 on Tolerance and Pharmacokinetics

NCT03510767
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT03510767

Comments are closed.

Up ↑